ArticleBritish journal of pharmacology2006
Vanilloid VR1 receptor is involved in rimonabant-induced neuroprotection.
Article in British journal of pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 78 citations in OpenAlex.
- Article
- Interrelated involvement of the endocannabinoid/endovanilloid (TRPV1) systems and epigenetic processes in anxiety- and working memory impairment-related behavioural effects of nicotine as a stressor.Addiction biology · 2024Article
- The Association between Spicy Food Consumption and Psychological Health in Chinese College Students: A Cross-Sectional Study.Nutrients · 2022Article
- Neuroprotective Effects of Cannabidiol but Not ΔInternational journal of molecular sciences · 2021Article
- Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox.Frontiers in endocrinology · 2021Review
- Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation.Antioxidants & redox signaling · 2018Review
- Surprising outcomes in cannabinoid CB1/CB2 receptor double knockout mice in two models of ischemia.Life sciences · 2018Article
- Perspectives of TRPV1 Function on the Neurogenesis and Neural Plasticity.Neural plasticity · 2016Review
- Fatty acid binding protein deletion suppresses inflammatory pain through endocannabinoid/N-acylethanolamine-dependent mechanisms.Molecular pain · 2015Article
- Psychiatric Disorders and TRP Channels: Focus on Psychotropic Drugs.Current neuropharmacology · 2015Review
- Disruption of ion homeostasis in the neurogliovascular unit underlies the pathogenesis of ischemic cerebral edema.Translational stroke research · 2014Review
- Article
- The biarylpyrazole compound AM251 alters mitochondrial physiology via proteolytic degradation of ERRα.Molecular pharmacology · 2013Article
- Unique effects of compounds active at both cannabinoid and serotonin receptors during stroke.Translational stroke research · 2012Article
- TRPV1: a stress response protein in the central nervous system.American journal of neurodegenerative disease · 2012Article
- Update on the role of cannabinoid receptors after ischemic stroke.Mediators of inflammation · 2012Review
- CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury.Microvascular research · 2009Article
- Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia.Trends in pharmacological sciences · 2009Review
- Article
- Role of cannabinoids and endocannabinoids in cerebral ischemia.Current pharmaceutical design · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, a potential neuroprotective effect of rimonabant, independent of the CB1 receptor interaction, has been proposed. In the present study, the role of transient receptor potential channel vanilloid subfamily member 1, named VR1, on neuroprotective effect of rimonabant, on global cerebral ischemia in gerbils, was investigated. Rimonabant (0.05-3 mg kg-1), given i.p. 5 min after recirculation, dose dependently antagonized the ischemia-induced decrease in electroencephalographic (EEG) total spectral power and restored relative frequency band distribution 7 days after ischemia. Rimonabant (0.125-0.5 mg kg-1) fully prevented ischemia-induced hyperlocomotion 1 day after ischemia and memory impairment evaluated in a passive avoidance task, 3 days after ischemia. At 7 days after ischemia, the survival of pyramidal cells, in the CA1 subfield, was respectively 91 and 96%, in the animals given rimonabant 0.25 and 0.5 mg kg-1, compared to the vehicle group. Higher doses were not protective. The protection induced by rimonabant followed a bell-shaped curve, the maximal active doses being 0.25 and 0.5 mg kg-1. Capsazepine (0.01 mg kg-1), a selective VR1 vanilloid receptor antagonist, completely reversed rimonabant-induced neuroprotective effects against EEG flattening, memory impairment and CA1 hippocampal neuronal loss. These findings suggest that VR1 vanilloid receptors are involved in rimonabant's neuroprotection even if other mechanisms can contribute to this effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.